Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in
treating patients with indolent non-Hodgkin's lymphoma. Monoclonal antibodies, such as
obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Giving obinutuzumab and ibrutinib may work better in treating patients with non-Hodgkin's
lymphomas.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University